Nav: Home

European experts highlight the potential of xenografts in personalized oncology

January 31, 2017

European research lays the foundation for the development of new and ambitious research projects with xenografts derived from patients, preclinical models with great potential to advance research and treatment in cancer. The review article, published in Nature Reviews Cancer, is the result of the joint work of the European consortium of researchers EurOPDX, which includes different researchers from the Bellvitge Biomedical Research Institute (IDIBELL) - Catalan Institute of Oncology (ICO), among which there are Eva González-Suárez and Alberto Villanueva.

Patient-derived xenografts are tumor samples that are extracted from patients and reimplanted in mice subcutaneously (PDXs) or orthotopically (PDOX or orthoxenografts), i.e., in the same location as in the patient. This mechanism constitutes an emerging platform to search for new treatments and biomarkers in oncology, since it allows to reproduce the behavior of each tumor in a personalized way and to test several treatment alternatives, integrating the genetic alterations characteristic of each tumor with the treatment.

"This review addresses the hottest topics in the field of subcutaneous models and orthoxenografts," explains Dr. Villanueva. "There are very important issues, such as how these models can be used for drug assessment, personalized medicine and cancer immunotherapy. This is a very broad review, based on a large amount of data from all members of the EurOPDX consortium of which we are part".

The EurOPDX consortium, created in 2013, integrates 16 European research institutions with extensive experience in basic, preclinical, translational and clinical oncology. Among its objectives is the creation of a collection of orthotopic and subcutaneous models for more than 30 diseases, the creation of a platform that allows the performance of preclinical studies at a multicentric level and the homogenization of methods and work practices to ensure the reproducibility of these studies.

At the Spanish level there are three research centers that make up the consortium. "At IDIBELL-ICO we are the European experts in orthohxenografts. More than 90% of these models have been generated in our facilities", says Dr. Villanueva, who in addition to being part of the proCURE research program of IDIBELL-ICO leads the spin-off company Xenopat, which specializes precisely in this type of model and in its use both for drug development and for performing personalized oncology studies.

Currently, the EurOPDX network of researchers is working to carry out a large-scale project - undergoing Horizon 2020 evaluation - which will attempt to validate a multicentric preclinical study with these models, that is, to demonstrate that the analysis of a single tumor of a single patient can yield the same results in different centers.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.